Interações de Alosetrona

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Concomitant use of fluvoxamine ( 4.3 ) (bula de Alosetrona, Contraindicações)

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (bula de Alosetrona, Interações medicamentosas)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (bula de Alosetrona, Interações medicamentosas)

Concomitant administration of alosetron and moderate CYP1A2 inhibitors, including quinolone antibiotics and cimetidine, has not been evaluated, but should be avoided unless clinically necessary because of similar potential drug interactions. (bula de Alosetrona, Interações medicamentosas)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

Fluvoxamine, a known strong inhibitor of CYP1A2, has been shown to increase mean alosetron plasma concentrations (AUC) approximately 6-fold and prolong the half-life by approximately 3-fold [see Drug Interactions ( 7.1 )] . (bula de Alosetrona, Contraindicações)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

Ketoconazole increased mean alosetron plasma concentrations (AUC) by 29%. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (bula de Eluxadolina, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

In patients taking ARAVA, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (bula de Leflunomida, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

Effects of Primaquine on the Pharmacokinetics of Other Drugs CYP1A2 Substrates Published clinical and non-clinical reports indicate primaquine inhibits CYP1A2 enzyme activity and thus may lead to increased exposure of CYP1A2 substrate drugs (e.g., duloxetine, alosetron, theophylline and tizanidine) when co-administered with Primaquine phosphate Tablets. (bula de Primaquina, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. (bula de Teriflunomida, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (bula de Alosetrona, Interações medicamentosas)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (bula de Alosetrona, Interações medicamentosas)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (bula de Alosetrona, Interações medicamentosas)

Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and hydralazine. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)

Another study showed that alosetron had no clinically significant effect on plasma concentrations of the oral contraceptive agents ethinyl estradiol and levonorgestrel (CYP3A4 substrates). (bula de Alosetrona, Interações medicamentosas)

The effect on CYP1A2 was explored further in a clinical interaction study with theophylline and no effect on metabolism was observed. (bula de Alosetrona, Interações medicamentosas)